World Library  
My Account |  Register |  Help  
  
Flag as Inappropriate
Email this Article
 

Levorphanol

Levorphanol
Systematic (IUPAC) name
17-methylmorphinan-3-ol
Clinical data
Trade names Levo-dromoran
AHFS/Drugs.com
MedlinePlus
Pregnancy
category
  • US: C (Risk not ruled out)
Legal status
Dependence
liability 		High
Routes of
administration 		oral, intravenous, subcutaneous, intramuscular
Pharmacokinetic data
Bioavailability 70% (oral); 100% (IV)
Protein binding 40%
Metabolism Hepatic
Biological half-life 11-16 hours
Identifiers
CAS Registry Number  Y
ATC code None
PubChem CID:
IUPHAR/BPS
DrugBank  Y
ChemSpider  Y
UNII  Y
KEGG  Y
ChEMBL  N
Chemical data
Formula C17H23NO
Molecular mass 257.371 g/mol
 N   

Levorphanol (Levo-Dromoran) is an opioid medication used to treat moderate to severe pain. Chemically it is (−)-3-hydroxy-N-methyl-morphinan.[1] It is the levorotatory stereoisomer of the synthetic morphinan (Dromoran) and a pure opioid agonist, first described in Germany in 1948 as an orally active morphine-like analgesic.[2] It has been in clinical use in the U.S. since the 1950s.[1] Levorphanol has opioid, NMDA antagonist and monoamine reuptake inhibitor activity; it binds strongly to the mu opioid receptor and less strongly to the kappa and delta opioid receptors but lacks complete cross-tolerance with morphine.[1] It possesses greater intrinsic activity at the MOR than morphine.[1] The duration of action is generally long compared to other comparable analgesics and varies from 4 hours to as much as 15 hours. For this reason levorphanol is useful in palliation of chronic pain and similar conditions. Levorphanol has an oral to parenteral effectiveness ratio of 2:1, one of the most favourable of the strong narcotics. Its NMDA actions, similar to those of the phenylheptylamine open-chain narcotics such as methadone or the phenylpiperidine ketobemidone, make levorphanol useful for types of pain that other analgesics may not be as effective against, such as neuropathic pain.[3]

Levorphanol is listed under the Single Convention On Narcotic Drugs 1961 and is regulated like morphine in most countries. In the United States it is a Schedule II Narcotic controlled substance with a DEA ACSCN of 9220 and 2013 annual aggregate manufacturing quota of 4.5 kilos. The salts in use are the tartrate (free base conversion ratio 0.58) and hydrobromide (0.76) [4]

Synthesis

By the resolution of the racemate (i.e. racemorphan):[5]

See also

References

  1. ^ a b c d Davis, MP; Glare, PA; Hardy, J (2009) [2005]. Opioids in Cancer Pain (2nd ed.). Oxford, UK: Oxford University Press.  
  2. ^ DE 1014545 
  3. ^ Prommer, E (2007). "Levorphanol: the forgotten opioid.". Supportive Care in Cancer 15 (3): 259–264.  
  4. ^ http://www.deadiversion.usdoj.gov/quotas/conv_factor/index.html
  5. ^ Schnider, O.; Gr�Ssner, A. (1951). "Oxy-morphinane. (3. Mitteilung). Optisch aktive 3-Oxy-morphinane". Helvetica Chimica Acta 34 (7): 2211.  


This article was sourced from Creative Commons Attribution-ShareAlike License; additional terms may apply. World Heritage Encyclopedia content is assembled from numerous content providers, Open Access Publishing, and in compliance with The Fair Access to Science and Technology Research Act (FASTR), Wikimedia Foundation, Inc., Public Library of Science, The Encyclopedia of Life, Open Book Publishers (OBP), PubMed, U.S. National Library of Medicine, National Center for Biotechnology Information, U.S. National Library of Medicine, National Institutes of Health (NIH), U.S. Department of Health & Human Services, and USA.gov, which sources content from all federal, state, local, tribal, and territorial government publication portals (.gov, .mil, .edu). Funding for USA.gov and content contributors is made possible from the U.S. Congress, E-Government Act of 2002.
 
Crowd sourced content that is contributed to World Heritage Encyclopedia is peer reviewed and edited by our editorial staff to ensure quality scholarly research articles.
 
By using this site, you agree to the Terms of Use and Privacy Policy. World Heritage Encyclopedia™ is a registered trademark of the World Public Library Association, a non-profit organization.
 


Copyright © World Library Foundation. All rights reserved. eBooks from Project Gutenberg are sponsored by the World Library Foundation,
a 501c(4) Member's Support Non-Profit Organization, and is NOT affiliated with any governmental agency or department.